Chronic Cough Market

Description

In 2024, the chronic cough market was valued at approximately US$ 9.15 billion and is anticipated to grow to US$ 13.60 billion by 2031. The market is projected to experience a compound annual growth rate (CAGR) of 8.2% from 2031 to 2031. Increased awareness of respiratory issues, advancements in medical research and treatment options, along with ongoing drug development trends, are expected to be significant factors influencing the chronic cough market.

Chronic Cough Market Analysis

The global chronic cough market is largely propelled by the rising incidence of chronic lung infections, as a persistent cough is a common symptom, and the introduction of new treatments for chronic cough. The market's growth is also supported by a notable shift towards prioritizing respiratory health and wellness, alongside initiatives from both governmental and non-governmental organizations.

Chronic Cough Market Overview

A chronic cough is defined as one that persists for eight weeks or longer. It can be caused by infections, asthma, and gastroesophageal reflux disease (GERD). Symptoms associated with chronic cough include a sensation of mucus running down the throat (postnasal drip), headaches, frequent throat clearing, sore throat, hoarseness, shortness of breath, wheezing, a sour taste in the mouth, and heartburn. There has been a notable increase in investments in healthcare infrastructure, diagnostic services, and patient education programs aimed at enhancing the management and early detection of chronic cough.

Strategic Insights

Chronic Cough Market Drivers and Opportunities

Increasing Incidence of Chronic Cough to Boost Market Growth

Conditions such as infections, lung diseases, and bronchitis are likely contributors to chronic cough. The global rise in asthma cases, particularly among children and adults, is significant. A study titled "Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study" published in February 2024, reported that the prevalence of chronic cough varies between 2% and 18%. Factors commonly linked to chronic cough include smoking, asthma, chronic obstructive pulmonary disease (COPD), obesity, upper airway cough syndrome (UACS), and gastroesophageal reflux disease (GERD).

Growing Elderly Population Expected to Increase Demand for Chronic Cough Treatments

Older adults are more susceptible to chronic cough, with aging being a primary factor in reduced immunity. Age-related degeneration of organs and healthy tissues can lead to various health issues, with chronic cough being prevalent among the elderly. As individuals age, their respiratory systems deteriorate, increasing the likelihood of respiratory infections such as pneumonia and influenza.

The global aging population is on the rise, with both developed and developing nations experiencing lower mortality rates. Improvements in healthcare have enhanced public health, leading to increased life expectancy. According to the World Health Organization (WHO), by 2050, the global population aged 60 and older is expected to reach 2.1 billion, with the number of individuals aged 80 and above projected to triple from 2020 to 2050, reaching 426 million. Consequently, the growing elderly demographic is likely to drive demand for chronic cough treatments during the forecast period.

Chronic Cough Market Report Segmentation Analysis

The chronic cough market analysis is segmented by drug class, route of administration, and distribution channel.

By drug class, the market includes antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and other classes. The combination drug segment held the largest market share in 2023.
In terms of route of administration, the market is categorized into oral, injections, inhalation, and other methods. The oral segment accounted for the largest market share in 2023.
Regarding distribution channels, the market is divided into hospital pharmacies, online pharmacies, and retail pharmacies, with the hospital pharmacy segment leading the market in 2023.

Chronic Cough Market Share Analysis by Geography

The geographic analysis of the chronic cough market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has been the leading region in the chronic cough market. The increasing demand for over-the-counter (OTC) products is a significant factor expected to drive revenue growth in this region during the review period. Additionally, the rising number of chronic cough cases, a rapidly growing elderly population, increasing vehicle pollution, and heightened awareness of advanced treatment options are contributing to the demand for cough remedy products.

Chronic Cough Market Report Scope

Chronic Cough Market News and Recent Developments

The chronic cough market evaluation is based on qualitative and quantitative data obtained from primary and secondary research, including key corporate publications, association data, and databases. Recent developments in the chronic cough market include:

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the initiation of its Phase 2b CORAL clinical trial for its investigational therapy Haduvio (oral nalbuphine ER) aimed at patients with chronic cough due to idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, evaluating three doses against placebo in approximately 160 IPF patients with chronic cough. (Source: Trevi Therapeutics, Press Release, 2023)
Algernon Pharmaceuticals Inc., a Canadian clinical-stage pharmaceutical development company, announced the completion of its agreement with Seyltx Inc., a privately owned U.S.-based drug development company, for the acquisition of Algernon's NP-120 (Ifenprodil) research program. (Source: Algernon Pharmaceuticals Inc., Press Release, 2024)

Chronic Cough Market Report Coverage and Deliverables

The report titled "Chronic Cough Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

Market size and forecast at global, regional, and country levels for all key segments included in the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter's Five Forces and SWOT analysis
Global and regional market analysis covering key trends, major players, regulations, and recent developments
Industry landscape and competition analysis including market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles

Product Code: TIPRE00011584

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Chronic Cough Market and By Drug Class
- 1.3.2 Chronic Cough Market and By Route of Administration
- 1.3.3 Chronic Cough Market and By Distribution Channel
- 1.3.4 Global Chronic Cough Market and By Geography

2. Chronic Cough Market and Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Chronic Cough Market and Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America andPEST Analysis
- 4.2.2 Europe and PESTAnalysis
- 4.2.3 Asia PacificandPEST Analysis
- 4.2.4 Middle East andAfrica and PEST Analysis
- 4.2.5 South and Central America
4.3 Expert Opinion

5. Chronic Cough Market and Key Market Dynamics

5.1 Market Drivers
- 5.1.1 RisingIncidences of Chronic Cough
- 5.1.2 Growing ProductDevelopments to Treat Chronic Cough
5.2 Market Restraints
- 5.2.1 Product Recalls
5.3 Market Opportunities
- 5.3.1 Aging Populationis Expected to Drive Demand for Chronic Cough Treatment
5.4 Future Trends
- 5.4.1 Continuous Trendof Drug Development
5.5 Impact Analysis

6. Chronic Cough Market and Global Analysis

6.1 Global Chronic Cough Market Revenue Forecast And Analysis
6.2 Global Chronic Cough Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Chronic Cough Market Analysis and By Drug Class

7.1 Overview
7.2 Chronic Cough Market Revenue Share, by Drug Class (2024 and 2031)
7.3 Antihistamines
- 7.3.1 Overview
- 7.3.2 Antihistamines:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.4 Corticosteroids
- 7.4.1 Overview
- 7.4.2 Corticosteroids:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.5 Decongestants
- 7.5.1 Overview
- 7.5.2 Decongestants:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.6 Combination Drug
- 7.6.1 Overview
- 7.6.2 CombinationDrug: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.7 Antibiotics
- 7.7.1 Overview
- 7.7.2 Antibiotics:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.8 Acid Blockers
- 7.8.1 Overview
- 7.8.2 Acid Blockers:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
7.9 Other Drug Class
- 7.9.1 Overview
- 7.9.2 Other DrugClass: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

8. Chronic Cough Market and By Route of Administration

8.1 Overview
8.2 Chronic Cough Market, by Route of Administration, 2024 and 2031 (%)
8.3 Oral
- 8.3.1 Overview
- 8.3.2 Oral: ChronicCough Market and Revenue and Forecast to 2031 (US$ Million)
8.4 Injections
- 8.4.1 Overview
- 8.4.2 Injections:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
8.5 Inhalation
- 8.5.1 Overview
- 8.5.2 Inhalation:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
8.6 Other Route of Administration
- 8.6.1 Overview
- 8.6.2 Other Route of Administration: Chronic Cough Market and Revenue and Forecast to 2031 (US$Million)

9. Chronic Cough Market and By Distribution Channel

9.1 Overview
9.2 Chronic Cough Market, by Distribution Channel, 2024 and 2031 (%)
9.3 Hospital Pharmacy
- 9.3.1 Overview
- 9.3.2 HospitalPharmacy: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
9.4 Online Pharmacy
- 9.4.1 Overview
- 9.4.2 Online Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
9.5 Retail Pharmacy
- 9.5.1 Overview
- 9.5.2 Retail Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

10. Chronic Cough Market and Geographic Analysis

10.1 North America: Chronic Cough Market
- 10.1.1 Overview
- 10.1.2 North America:Chronic Cough Market and Revenue and Forecast to 2031 (USD Million)
- 10.1.3 North America:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.1.4 North America:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.1.5 North America:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.6 North America:Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.1.7 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.1.7.1 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.1.7.2 US: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.7.3 US: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.7.4 US: Chronic Cough Market,by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.8 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.8.1 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.8.2 Canada: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.8.3 Canada: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.8.4 Canada: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.1.9 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.9.1 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.1.9.2 Mexico: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.1.9.3 Mexico: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.1.9.4 Mexico: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
10.2 Europe: Chronic Cough Market
- 10.2.1 Overview
- 10.2.2 Europe: ChronicCough Market - Revenue and Forecast to 2031 (USD Million)
- 10.2.3 Europe: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.2.4 Europe: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.2.5 Europe: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.6 Europe: ChronicCough Market, by Country, 2018 and 2031 (%)
- 10.2.7 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.7.1 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.7.2 Germany: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.2.7.3 Germany: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.7.4 Germany: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.8 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.8.1 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.8.2 UK: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.8.3 UK: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.9 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.9.1 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.2.9.2 France: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.9.3 France: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.9.4 France: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.10 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.10.1 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.10.2 Spain: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.10.3 Spain: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.10.4 Spain: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.2.11 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.11.1 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.2.11.2 Italy: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.2.11.3 Italy: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.2.11.4 Italy: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
10.3 Asia Pacific: Chronic Cough Market
- 10.3.1 Overview
- 10.3.2 Asia Pacific:Chronic Cough Market - Revenue and Forecast to 2031 (USD Million)
- 10.3.3 Asia Pacific:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.3.4 Asia Pacific:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
- 10.3.5 Asia Pacific:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.6 Asia Pacific:Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.3.7 China: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.7.1 China: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.7.2 China: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.7.3 China: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.7.4 China: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.8 Japan: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.8.1 Japan: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.8.2 Japan: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.8.3 Japan: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.8.4 Japan: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.9 India: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.9.1 India: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
  - 10.3.9.2 India: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.9.3 India: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.9.4 India: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.10 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.10.1 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.10.2 South Korea: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.10.3 South Korea: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.10.4 South Korea: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.3.11 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.11.1 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.3.11.2 Australia: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
  - 10.3.11.3 Australia: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
  - 10.3.11.4 Australia: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
10.4 Middle East and Africa: Chronic Cough Market
- 10.4.1 Overview
- 10.4.2 Middle East andAfrica: Chronic Cough Market- Revenue and Forecast to 2031 (USD Million)
- 10.4.3 Middle East andAfrica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.4.4 Middle East andAfrica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
- 10.4.5 Middle East andAfrica: Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.6 Middle East andAfrica: Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.4.7 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.7.1 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.7.2 Saudi Arabia:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.7.3 Saudi Arabia:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.7.4 Saudi Arabia:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.8 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.8.1 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.8.2 UAE: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.8.3 UAE: Chronic CoughMarket, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.8.4 UAE: Chronic Cough,Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.4.9 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.9.1 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
  - 10.4.9.2 South Africa:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.4.9.3 South Africa:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.4.9.4 South Africa:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
10.5 South and Central America: Chronic Cough Market
- 10.5.1 Overview
- 10.5.2 South and CentralAmerica: Chronic Cough Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 South and CentralAmerica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
- 10.5.4 South and CentralAmerica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
- 10.5.5 South and CentralAmerica: Chronic Cough Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 10.5.6 South and CentralAmerica: Chronic Cough Market, by Country, 2024 and 2031 (%)
- 10.5.7 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.7.1 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.7.2 Brazil: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.5.7.3 Brazil: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.5.7.4 Brazil: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
- 10.5.8 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.8.1 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
  - 10.5.8.2 Argentina: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
  - 10.5.8.3 Argentina: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
  - 10.5.8.4 Argentina: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)

11. Impact of COVID-19 Pandemic on Global Chronic cough Market

11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Chronic Cough Market andIndustry Landscape

12.1 Overview
12.2 Growth Strategies in The Chronic Cough Market, 2016-2020
12.3 Inorganic Growth Strategies
- 12.3.1 Overview
12.4 Organic Growth Strategies
- 12.4.1 Overview

13. COMPANY PROFILES

13.1 Novartis AG
- 13.1.1 Key Facts
- 13.1.2 BusinessDescription
- 13.1.3 Products andServices
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.2.1 Key Facts
- 13.2.2 BusinessDescription
- 13.2.3 Products andServices
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 BusinessDescription
- 13.3.3 Products andServices
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 BusinessDescription
- 13.4.3 Products andServices
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 MYLAN N.V.
- 13.5.1 Key Facts
- 13.5.2 BusinessDescription
- 13.5.3 Products andServices
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Amneal Pharmaceuticals, Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products andServices
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Cipla Inc.
- 13.7.1 Key Facts
- 13.7.2 BusinessDescription
- 13.7.3 Products andServices
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Reckitt Benckiser Group plc.
- 13.8.1 Key Facts
- 13.8.2 BusinessDescription
- 13.8.3 Products andServices
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Sun Pharmaceutical Industries Ltd
- 13.9.1 Key Facts
- 13.9.2 BusinessDescription
- 13.9.3 Products andServices
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Aurobindo Pharma Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary of Terms